The clinical investigator最新文献_第6页

Pneumococcal parotitis and cervical lymph node abscesses in an HIV-infected patient. hiv感染患者的肺炎球菌性腮腺炎和颈部淋巴结脓肿。

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577751

H J Stellbrink, H Albrecht, H Greten

引用次数: 7

Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma. 白细胞介素-2和干扰素- α 2b治疗转移性黑色素瘤患者促甲状腺激素分泌的抑制

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577739

H Mönig, A Hauschild, S Lange, U R Fölsch

{"title":"Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.","authors":"H Mönig, A Hauschild, S Lange, U R Fölsch","doi":"10.1007/BF00577739","DOIUrl":"https://doi.org/10.1007/BF00577739","url":null,"abstract":"Recent reports suggest that combined therapy with recombinant interleukin (IL)-2 and interferon (IFN) alpha 2b may result in autoimmune-induced thyroid dysfunction. We prospectively analyzed thyroid function for 6 weeks in two groups of patients with progressive metastatic melanoma treated according to two different protocols. In group I (n = 17) three treatment cycles were given, each with three weeks of subcutanous administration of rIL-2 and INF-alpha 2b at different doses. In group II (n = 13) the chemotherapeutic agent dacarbazine was given in addition. In group 1 three patients developed frank hyperthyroidism, which required antithyroid drug therapy in one case. Autoantibodies against thyroid microsomal antigen, thyroglobulin, and the thyroid-stimulating hormone (TSH) receptor were not significantly elevated in any of these patients. However, the remaining 14 patients showed a significant decrease in TSH after 6 weeks of treatment, from 1.8 +/- 0.9 to 0.7 +/- 0.7 microU/ml (P < 0.02). Thyroid hormones (triiodothyronine, thyroxine, free thyroxine) also increased during the observation time, but this did not parallel the drop in TSH levels. Only thyroxine increased above the upper limit of normal, while triiodothyronine and free thyroxine stayed within the normal range. In group II, 6 of 13 patients (46%) had a decreased TSH after 6 weeks of treatment. Mean TSH was 1.5 +/- 1.4 before and 0.8 +/- 0.6 microU/ml after 6 weeks and was totally suppressed in three cases. None of these patients showed ouvert hyperthyroidism. Hypothyroidism was not observed in either group.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":22408,"journal":{"name":"The clinical investigator","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00577739","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18715734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands. 原发性醛固酮增多症:肾上腺腺瘤和双侧肾上腺增生的临床表现和长期随访的差异。

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577740

T Jeck, B Weisser, T Mengden, L Erdmenger, S Grüne, W Vetter

{"title":"Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.","authors":"T Jeck, B Weisser, T Mengden, L Erdmenger, S Grüne, W Vetter","doi":"10.1007/BF00577740","DOIUrl":"https://doi.org/10.1007/BF00577740","url":null,"abstract":"Since 1974 primary aldosteronism has been diagnosed in 71 patients in our outpatient clinic. Thirty-four patients had a unilateral aldosterone-producing adenoma, whereas bilateral adrenal hyperplasia was diagnosed in 37 patients. Although at the time of diagnosis the mean potassium values were lower and mean aldosterone levels were higher in patients with an adenoma, as compared to those with bilateral hyperplasia, these laboratory data did not allow us to differentiate between the two leading causes of primary aldosteronism in the individual patient due to pronounced overlap of laboratory values between the two groups. During the first few years, a successful differential diagnosis was made by adrenal phlebography and separate sampling of plasma aldosterone in both adrenal veins; later non-invasive imaging techniques such as computed tomography and radionuclide scanning were used. The best results were obtained in patients with adenoma who underwent adrenalectomy. Fifty-six percent of these patients were clinically and biochemically cured; 28% were improved and had normal blood pressure values during drug treatment. In contrast, patients with bilateral hyperplasia were treated pharmacologically, but only in half of the patients could normal blood pressure values be achieved. Two thirds of the male patients developed gynecomastia during spironolactone treatment. As expected, unilateral adrenalectomy was unsuccessful in the 7 patients with bilateral hyperplasia who underwent surgery. Our results confirm that surgical treatment of adrenal adenomas and drug treatment of bilateral hyperplasias are the appropriate therapy in primary aldosteronism. A differential diagnosis cannot be made on the basis of clinical and non-invasive laboratory data alone; imaging techniques have to be included in the diagnostic process.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":22408,"journal":{"name":"The clinical investigator","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00577740","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18715735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Are heart rate responses reproducible in the tilt-table test? 在倾斜试验中心率反应可重复吗?

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577743

W H Jost, C Rapp, J König, K Schimrigk

引用次数: 2

Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. 正常人长期口服别嘌呤醇和氢氯噻嗪时的相互作用。2别嘌呤醇、氧化嘌呤醇和氢氯噻嗪的动力学。

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577759

J X de Vries, A Voss, A Ittensohn, I Walter-Sack, W Löffler, R Landthaler, N Zöllner

{"title":"Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.","authors":"J X de Vries, A Voss, A Ittensohn, I Walter-Sack, W Löffler, R Landthaler, N Zöllner","doi":"10.1007/BF00577759","DOIUrl":"https://doi.org/10.1007/BF00577759","url":null,"abstract":"The kinetics of allopurinol and hydrochlorothiazide were investigated in seven healthy male subjects during prolonged coadministration of two drugs. Subjects were maintained on an isoenergetic, purine-free formula diet with RNA supplementation for 24 days. Allopurinol (300 mg) was given orally on days 1-24. Hydrochlorothiazide (50 mg daily) was added to days 11-21. On day 43 a single oral dose of 50 mg hydrochlorothiazide was administered. Plasma concentration-time profiles of allopurinol and its main metabolite oxipurinol were obtained on days 1, 10, and 21; hydrochlorothiazide profiles were assessed on days 21 and 43. In addition, 24-h plasma concentrations of oxipurinol were measured repetitively, and 24 h urine samples were collected for the determination of allopurinol, oxipurinol, and hydrochlorothiazide. For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively. The small difference in AUC0-24 values does not explain the increase in plasma uric acid concentration during hydrochlorothiazide treatment, nor do the variations in allopurinol and hydrochlorothiazide kinetics.","PeriodicalId":22408,"journal":{"name":"The clinical investigator","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00577759","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18712641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Urinary zinc excretion and acute phase response in cancer patients. 癌症患者尿锌排泄与急性期反应。

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577746

B Melichar, P Jandik, M Tichy, F Malir, J Mergancova, Z Voboril

引用次数: 8

Development of resistance by Enterobacter cloacae during therapy of pulmonary infections in intensive care patients. 重症监护患者肺部感染治疗过程中阴沟肠杆菌耐药性的发展。

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577747

R Füssle, J Biscoping, R Behr, A Sziegoleit

引用次数: 5

Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations. 单氟磷酸钙-碳酸钙或氟化钠治疗后血清氟化物水平的比较:血清峰值浓度的差异

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577760

L Erlacher, H Teufelsbauer, P Bernecker, P Pietschmann, M Weissel

{"title":"Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations.","authors":"L Erlacher, H Teufelsbauer, P Bernecker, P Pietschmann, M Weissel","doi":"10.1007/BF00577760","DOIUrl":"https://doi.org/10.1007/BF00577760","url":null,"abstract":"Fluoride salts are widely used in Europe in the treatment of established osteoporosis with crush fractures for their ability to increase trabecular bone mass. However, in the United States fluorides are still regarded as an experimental drug. In a prospective, randomized study we compared the fluoride pharmacokinetics of enteric-coated sodium fluoride and disodium monofluorophosphate calcium carbonate (MFP-Ca) over the period of 76 h. Twenty subjects (12 females, 8 males), aged 35-80 years, free of gastrointestinal disorders, renal impairment, and liver disease and without prior fluoride intake entered the study. Ten subjects received NaF (11.3 mg fluoride) twice a day and the other ten MFP-Ca (13.2 mg fluoride) twice a day. During the study period of 76 h the patient's usual food intake was not changed. Serum fluoride levels were determined using an ion sensitive electrode. After intake of a single drug preparation of MFP-Ca or NaF, MFP-Ca showed a significantly shorter lag time of absorption and a significantly higher maximal serum fluoride concentration than NaF (P < 0.01). A comparison of fluoride cumulative characteristics of both drugs showed virtually identical serum fluoride levels before intake of the morning dose on all 4 study days, whereas serum fluoride concentrations measured 4 h afterwards were significantly higher for MFP-Ca than for NaF. These data provide evidence of high \"peak\" serum fluoride levels for MFP-Ca, whereas only small peak-to-trough fluctuations are seen for NaF.","PeriodicalId":22408,"journal":{"name":"The clinical investigator","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00577760","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18712642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Habent sua fata libelli (books have their fate) 他们有他们的命运

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577731

N Zöllner

引用次数: 0

Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study. 普伐他汀和吉非齐治疗家族性载脂蛋白B-100缺陷患者:一项两期交叉研究

The clinical investigator Pub Date : 1994-12-01 DOI: 10.1007/BF00577757

P S Hansen, H Meinertz, L U Gerdes, I C Klausen, O Faergeman

引用次数: 6